Aprameya Engineering Limited — PPTs, 08-05-2025: Investor Presentation

1. Financial Highlights:

Aprameya Engineering nearly doubled revenue to Rs 1,363 Mn in FY25 from Rs 652 Mn last year. EBITDA rose sharply to Rs 250 Mn with an 18% margin, up from 10%, showing improved efficiency. PAT increased to Rs 161 Mn (12% margin). ROE remained steady at 10%, while ROCE improved to 26%, indicating better capital use. Networth expanded to Rs 643 Mn and debt dropped to Rs 304 Mn, strengthening the balance sheet. Operating cash flow was negative due to working capital, but financing cash flows supported growth.

2. Strategic Initiatives & Growth Drivers:

The company is expanding geographically into Bihar, Sikkim, Odisha, Chhattisgarh, Daman, and deepening Maharashtra presence. Product focus includes Modular OTs, Mobile CTs, MRIs, Integrated OTs, and robotic surgical systems. It aims to boost recurring service revenues via AMC/CAMC contracts and deepen collaborations with top medical equipment manufacturers. Operational improvements target faster project execution and supply chain efficiencies.

3. Business Developments:

Aprameya has a Rs 600 Mn order book across Maharashtra, Rajasthan, Gujarat, Delhi, and Bihar to be executed over 5–6 months. Key wins include turnkey healthcare projects, modular OT complexes, 3D electrophysiological mapping systems, and maintenance contracts. It holds authorized distributorships for brands like Johnson & Johnson, Schiller, Phillips, Alan Electronics, and ResMed.

4. Market Position & Competitive Advantage:

The company differentiates itself as a leading turnkey healthcare infrastructure provider offering faster project delivery and single-vendor solutions. Strong ties with government bodies, AIIMS, and private hospitals support its market position. Its integrated approach spans construction, equipment supply, and long-term service, addressing India’s fragmented healthcare infrastructure space uniquely.

5. Investor Implications:

Robust financial growth and a solid order book underscore positive growth potential amid healthcare capacity upgrades and tech adoption. Geographic and product diversification plus recurring service revenues improve earnings visibility. Aprameya appears well placed to benefit from India’s underpenetrated healthcare infrastructure with limited execution risk based on its track record and partnerships.